http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105085656-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39516 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2015-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105085656-B |
| titleOfInvention | The application of P19/Ebi3 compounds and its polyclonal antibody in systemic loupus erythematosus diagnosis and treatment |
| abstract | The invention discloses the purposes of P19/Ebi3 compounds and its polyclonal antibody in systemic lupus erythematosus diagnosis, treatment.Experiment proves, compared with normal mouse, P19/Ebi3 compound high level expressions in systemic loupus erythematosus mouse, and the expression of mouse internal antibody and the number of immunocyte can be reduced using the polyclonal antibody of anti-P19/Ebi3 albumen, showing can be by preparing the antibody of anti-P19/Ebi3 come systemic lupus erythematosus, therefore P19/Ebi3 compounds and its inhibitor are used to prepare diagnosis and treatment system lupus erythematosus medicine, have good development prospect. |
| priorityDate | 2015-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 135.